Osborne CK - Search Results

1

Mitosin (a new proliferation marker) correlates with clinical outcome in node-negative breast cancer.

Clark GM, Allred DC, Hilsenbeck SG, Chamness GC, Osborne CK, Jones D, Lee WH. Clark GM, et al. Among authors: osborne ck. Cancer Res. 1997 Dec 15;57(24):5505-8. Cancer Res. 1997. PMID: 9407959

2

Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer.

Allred DC, Clark GM, Molina R, Tandon AK, Schnitt SJ, Gilchrist KW, Osborne CK, Tormey DC, McGuire WL. Allred DC, et al. Among authors: osborne ck. Hum Pathol. 1992 Sep;23(9):974-9. doi: 10.1016/0046-8177(92)90257-4. Hum Pathol. 1992. PMID: 1355464

3

HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma.

Allred DC, Clark GM, Tandon AK, Molina R, Tormey DC, Osborne CK, Gilchrist KW, Mansour EG, Abeloff M, Eudey L, et al. Allred DC, et al. Among authors: osborne ck. J Clin Oncol. 1992 Apr;10(4):599-605. doi: 10.1200/JCO.1992.10.4.599. J Clin Oncol. 1992. PMID: 1548522 Clinical Trial.

4

Inhibition of breast cancer cell growth in vitro by a tyrosine kinase inhibitor.

Reddy KB, Mangold GL, Tandon AK, Yoneda T, Mundy GR, Zilberstein A, Osborne CK. Reddy KB, et al. Among authors: osborne ck. Cancer Res. 1992 Jul 1;52(13):3636-41. Cancer Res. 1992. PMID: 1617636

5

Prognostic potential of DNA flow cytometry measurements in node-negative breast cancer patients: preliminary analysis of an intergroup study (INT 0076).

Dressler LG, Eudey L, Gray R, Tormey DC, McGuire WL, Gilchrist KW, Clark GM, Osborne CK, Mansour EG, Abeloff MD. Dressler LG, et al. Among authors: osborne ck. J Natl Cancer Inst Monogr. 1992;(11):167-72. J Natl Cancer Inst Monogr. 1992. PMID: 1627424 Clinical Trial.

6

Dose intensity as a therapeutic strategy in breast cancer.

Osborne CK. Osborne CK. Breast Cancer Res Treat. 1991 Dec;20 Suppl:S11-4. doi: 10.1007/BF01908239. Breast Cancer Res Treat. 1991. PMID: 1687202

7

Prognostic significance of S-phase fraction in good-risk, node-negative breast cancer patients.

Clark GM, Mathieu MC, Owens MA, Dressler LG, Eudey L, Tormey DC, Osborne CK, Gilchrist KW, Mansour EG, Abeloff MD, et al. Clark GM, et al. Among authors: osborne ck. J Clin Oncol. 1992 Mar;10(3):428-32. doi: 10.1200/JCO.1992.10.3.428. J Clin Oncol. 1992. PMID: 1740681

8

Hematopoietic growth factors in breast cancer--overview.

Osborne CK. Osborne CK. Breast Cancer Res Treat. 1991 Dec;20 Suppl:S1-2. doi: 10.1007/BF01908237. Breast Cancer Res Treat. 1991. PMID: 1806028 No abstract available.

9

Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerization of trans-4-hydroxytamoxifen.

Osborne CK, Coronado E, Allred DC, Wiebe V, DeGregorio M. Osborne CK, et al. J Natl Cancer Inst. 1991 Oct 16;83(20):1477-82. doi: 10.1093/jnci/83.20.1477. J Natl Cancer Inst. 1991. PMID: 1920493

10

Tamoxifen in premenopausal patients with metastatic breast cancer: a review.

Sunderland MC, Osborne CK. Sunderland MC, et al. Among authors: osborne ck. J Clin Oncol. 1991 Jul;9(7):1283-97. doi: 10.1200/JCO.1991.9.7.1283. J Clin Oncol. 1991. PMID: 2045868 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

376 results

Search Page

Filters